Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: A novel small molecule glycolysis inhibitor WZ35 exerts anti-cancer effect via metabolic reprogramming

Fig. 4

WZ35 inhibits growth of liver cancer cells in a ROS-dependent manner. A The levels of intracellular reactive oxygen species (ROS) were determined by measuring the mean fluorescence intensity (MFI) of DCFH-DA (DCF) via flow cytometry in control or WZ35-treated HCCLM3 cells following pretreatment with NAC. Results are presented as the mean ± standard error from independent experiments in triplicate. ***P < 0.001, student’s t test. B–D HCCLM3 cells with or without NAC (5 mM) pretreatment were incubated with or without WZ35 (10 μg/mL) to assess the cellular proliferation via CCK-8 assays B and colony formation assays C, assess cellular apoptosis via DAPI staining assays D with representative images and/or quantifications have been shown. E Western blotting analysis of the protein level of YAP and CTGF in HCCLM3 cells treated with NAC and WZ35. All these results are presented as the mean ± standard error from independent experiments in triplicate. **P < 0.01, ***P < 0.001, student’s t test

Back to article page